Extavia FDA Approval History
FDA Approved: Yes (First approved August 14, 2009)
Brand name: Extavia
Generic name: interferon beta-1b
Company: Novartis Pharmaceuticals Corporation
Treatment for: Multiple Sclerosis
Extavia is a branded version of interferon beta-1b, a first-line disease-modifying therapy that has been a standard-of-care for multiple sclerosis for many years. Extavia is indicated for the treatment of MS patients with relapsing forms of the disease and for newly diagnosed patients.
Development timeline for Extavia
| Date | Article |
|---|---|
| Aug 17, 2009 | Approval US FDA Approves Extavia - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with This Devastating Disease |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
